Refractory Primary Central Nervous System Lymphoma
3 clinical trials · Condition
◉ Watch Refractory Primary Central Nervous System Lymphoma
| Record | Firm | Date |
|---|---|---|
| Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) (NCT04947319) | Ono Pharmaceutical Co., Ltd. | 2021-12-29 |
| CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) (NCT03328078) | Curis, Inc. | 2017-12-28 |
Track Refractory Primary Central Nervous System Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.